James Sapirstein, Chief Executive Officer at ContraVir Pharmaceuticals, Inc. (CTRV), bought 500 shares at $2.15 ($1K) on 2015-11-30, disclosed to the SEC on 2015-12-01.
Open-market purchase of $1k CTRV by Chief Executive Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| FWBI | SELL | 2024-03-19 | $9K | — | Filing → |
| FWBI | SELL | 2024-01-17 | $697 | — | Filing → |
| FWBI | SELL | 2023-10-06 | $802 | — | Filing → |